

# LSTCON

**ONLINE OCTOBER 27-28**

**SPECIAL POST-ELECTION SESSION NOVEMBER 17**

**LIFE-SAVING SCIENCE    MADE IN TENNESSEE**

Our industry has risen to meet the challenge of COVID-19 and will deliver novel diagnostic tests, therapeutic treatments and preventative vaccines to combat and eradicate the virus.

That's why LSTCON will look to the future and showcase ways Tennessee companies and institutions are innovating cures for other diseases and conditions, as well as the state and federal policies that impact these innovations.



**LIFE SCIENCE**  
TENNESSEE



# Our Commitment to *Beat* Coronavirus

In these unprecedented times, America's biopharmaceutical companies are coming together to achieve one shared goal: the eradication of COVID-19. The decades-long investments we made in new technology, research and treatments have prepared us to act swiftly:

- We are rapidly screening our vast global libraries of medicines to identify potential treatments and have numerous clinical trials underway to test new and existing therapies
- We are dedicating our top scientists and using our investments in new technologies to speed the development of safe and effective vaccines
- We are sharing the learnings from clinical trials in real time with governments and other companies to advance the development of additional therapies
- We are expanding our unique manufacturing capabilities and sharing available capacity to ramp up production once a successful medicine or vaccine is developed
- We are collaborating with government agencies, hospitals, doctors and others to donate supplies and medicines to help those affected around the world
- We are working with governments and insurers to ensure that when new treatments and vaccines are approved they will be available and affordable for patients

We all have unique roles to play and are confident that together we can be successful. And we won't rest until we are.

Learn more at [PhRMA.org/coronavirus](https://PhRMA.org/coronavirus) and [bio.org/coronavirus](https://bio.org/coronavirus)

4 - 5:30 PM CT

### Tennessee Life Science Companies on the Front Lines of Cures:

Scientific research and development don't stop because of a pandemic. But COVID-19 has impacted companies building technologies for other conditions. Hear from a panel of innovators representing everything from diagnostics and drugs to devices and CMOs about the challenges and opportunities they face in Tennessee to raise capital, maintain a workforce, and carry on their life-saving missions.

- **Jenn Adams, CEO, August Bioservices**  
Jenn has been serving in healthcare leadership roles for over 30 years. She has extensive experience leading, transforming, and driving growth in both Fortune 500 public and private equity-backed companies, as well as deep expertise within the outsourced pharmaceutical services sector.
- **Kayla Graff, Co-Founder and CEO, SweetBio**  
Kayla is a thought-provoking business leader bringing a fresh perspective to the healthcare and wound care industries. As CEO and co-founder of SweetBio, Kayla has spearheaded fundraising to bring APIS from product development through patenting, FDA clearance, and early commercialization.
- **Brian Laden, President and COO, Appello Pharmaceuticals**  
Brian is the president and COO of Appello Pharmaceuticals, a science-driven company focused on improving the lives of Parkinson's disease patients through novel drug therapy. Previously, Brian was a Co-founder and Partner at TriStar Health Partners, a venture capital investment group managing early stage healthcare and life science-focused funds.
- **Dan Liebler, PhD, President and CEO, Protypia, Inc.**  
Dan is the founder, president and CEO of Protypia, Inc., a biotechnology company that provides analytical proteomics solutions to support the development of new immunotherapeutics for oncology and autoimmune diseases. He also is an Adjunct Professor of Biochemistry at Vanderbilt University School of Medicine. Dan has over 30 years' experience at the interface of analytical technology, chemical biology and disease research and was elected a Fellow of the American Association for the Advancement of Science and a Fellow of the American Chemical Society.

## Shaping the Future of Cures:

The COVID-19 pandemic has swiftly reshaped the policy and regulatory environment. Investment continues to flood into biotech and biopharma companies who have virus-related applications. The regulatory environment is operating at a fast clip—dare we say warp speed. How will these changes impact future research and development? What of these changes, such as the reliance on telemedicine, will stick around? Hear from legislators at the state and federal levels about the role of policymakers in shaping this environment.

### ➤ **Rep. Phil Roe, MD (R-1), U.S. House of Representatives**

Congressman Phil Roe represents the First Congressional District of Tennessee in the U.S. House of Representatives. He will be retiring from the House at the end of this term. As a physician, earning his medical degree from the University of Tennessee, Congressman Roe has become an active player in the effort to reform our nation's health care system. He is the co-chair of the House GOP Doctors Caucus and a co-chair of the Congressional Academic Medicine Caucus.

### ➤ **Sen. Shane Reeves (R-14), Tennessee General Assembly**

Senator Shane Reeves was elected to represent Tennessee's 14th District in the Senate in a special election in 2018. In the General Assembly, Sen. Reeves is the 2nd Vice-Chair of the Senate Health & Wellness Committee and a member of both the Senate Energy, Agriculture, and Natural Resources and the Senate State & Local Government Committees. Prior to public office, Sen. Reeves was a pharmacist and founded TwelveStone Health Partners.

### ➤ **Zach Poss, PhRMA**

Zach Poss is Senior Manager of State Policy for PhRMA. In his tenure, he has worked with states on a wide-range of health policy issues throughout the Southeast and Midwest. Prior to working at PhRMA, Zach interned with Senator Lamar Alexander, then chair of the Senate HELP Committee. Zach is a proud graduate of the American University, where he earned his Bachelor of Arts in Political Science and George Washington University, where he earned his Master of Public Policy.



# DRIVING BUSINESS, PRACTICING LAW.

waller

[wallerlaw.com](http://wallerlaw.com)

NASHVILLE

AUSTIN

BIRMINGHAM

CHATTANOOGA

MEMPHIS



# LSTCONprogram

Wednesday, October 28

10:00 AM CT

## Fund It:

Are you in the process of raising capital for your life science company? Hear tips from Rob Readnour and David Adair for perfecting your pitch—and ensuring your science is rock solid.

➤ **Rob Readnour, PhD, Managing Director, Mountain Group Partners**  
Rob is an internationally recognized expert on animal health product development, analytical chemistry, human food safety, and drug residues. Throughout his career, Rob was responsible for the development and commercialization of 10 animal health products. He currently serves on a number of Life Sciences, Agtech, and Technology sector organizations.

➤ **David Adair, MD, Co-Founder and Managing Director, Solas BioVentures**  
David is one of the founding members of Solas BioVentures where he currently focuses on investments in medical device and therapeutic companies. Board certified in Maternal-Fetal Medicine, Obstetrics and Gynecology, and Hypertension, with special expertise in Critical Care, David is a long-time physician, educator, administrator, innovator, and biotech/med-tech investor with nearly 20 years' experience in angel and venture investing.

11:00 AM CT

## Build It:

How do you grow an industry while maintaining a steadfast hold of your mission? Learn about the ways LST is expanding the life science industry in Tennessee and the important role you play in this effort with board chairman Ted Townsend.

➤ **Ted Townsend, Chief Economic Development Officer, Greater Memphis Chamber, the University of Memphis**  
Ted leads an economic and government relations collaborative between the University of Memphis and the Greater Memphis Chamber focused on the growth and prosperity of the region's economy by promoting Memphis to companies in national and international markets. Prior, Ted served the State of Tennessee's Department of Economic and Community Development, with nearly half of that term as Deputy Commissioner and Chief Operating Officer.

# LSTCONprogram

Wednesday, October 28

## Build It:

### › Abby Trotter, Executive Director, Life Science Tennessee

Abby has served as executive director of Life Science Tennessee since 2012 bringing a keen focus on policy initiatives to the organization along with significant membership growth. Under Abby's leadership, Life Science TN has seen major developments including the formation of a mentor network; an annual Venture Forum; the development of a life science caucus in the Tennessee General Assembly; and a strategic alignment with BioTN, a non-profit organization focused on workforce development and economic development for the industry. She couldn't do it without a great staff in Sara Pruneski and Danielle Pyle, among others.

1:00 PM CT

## Secure It:

Hear tips from Julie Lampley and Danielle Sloane about how to navigate the complex maze of federal and state healthcare laws and regulations and ensure compliance in an ever-changing landscape.

### › Julie Lampley, Epstein Becker Green

Julie is a Member of the Firm in the Health Care and Life Sciences practice, in the Nashville and Memphis offices of Epstein Becker Green. She focuses on health care regulatory and compliance law, mergers and acquisitions, commercial contracting (with an emphasis on health care entities), and antitrust law. Julie represents pharmaceutical and medical device companies, academic medical centers, and other institutional health care providers, offering creative and solution-driven counsel and advocacy.

### › Danielle Sloane, Member, Bass, Berry & Sims

Danielle helps national life science and health care clients navigate the complex maze of federal and state health care laws and regulations. With an analytical eye, Danielle helps her clients mitigate legal risk and achieve regulatory compliance consistent with their business goals. She works with clients ranging from hospitals and ambulatory surgical centers to medical device companies and laboratories.



# LSTCONprogram

Wednesday, October 28

2:00 PM CT

## Translate It:

How do you commercialize life-saving science? Get off the bench and hear from Dr. Larry Marnett, and Dr. Richard Magid, about their experiences bringing drugs and therapies to market.

**Larry Marnett, PhD, Dean of Basic Sciences, Vanderbilt University School of Medicine**

Lawrence J. Marnett, Ph.D., is currently Dean of Basic Sciences at Vanderbilt University. Marnett's research program focuses on the role of bioactive lipids in cancer and inflammation. He is the author of over 500 research publications and 14 patents and has received an American Cancer Society Faculty Research Award, an Outstanding Investigator Award, and a MERIT Award from the National Cancer Institute.

**Richard Magid, PhD, Vice President, University of Tennessee Research Foundation at UT Health Science Center**

Dr. Richard Magid is vice president of UTRF at the UT Health Science Center and manages the operations of the Memphis office. This office is responsible for all aspects of the commercialization of technologies developed at the UTHSC.

4 -5:30 PM CT

**Venture Forum:** Our annual pitch competition for life science startups, sponsored by Waller.

## LST Update and Voting:

Hear about LST's priorities for the coming year and vote for our new board—including a new board chairman. Your voice (and vote) matter as a member!

## Mark you calendars!

Don't miss a special session on November 17 at 4:00 - 5:00 PM CT for a post election analysis and a discussion of the implications of the results for our industry.

Wednesday, October 28

## VENTURE FORUM 4 - 5:30 PM CT

Sponsored by Waller, the Venture Forum gives a platform to emerging life science startups to access funding and potential investment opportunities, as well as marketing support. Each company will have 10 minutes to pitch before a panel of judges who will evaluate each team on IP and commercialization strategy. Finalists will compete for a \$5k prize awarded by Waller.

The following companies are 2020 Venture Forum finalists:

- **Diatech Diabetes**, headquartered in Memphis, is developing a patent-pending smart infusion set that monitors and alerts patients with insulin-dependent diabetes and their caretakers of insulin pump delivery malfunctions. Their product, SmartFusion, is a sensor-based infusion set for insulin pumps that monitors insulin delivery for accuracy and infusion abnormalities.
- **Ichor Sciences** is a Nashville-based company that has developed the StatBond, a hemostatic device built to provide both a localized sealant to prevent blood loss and a physical scaffold the body can use to build a clot.
- **MiCare Path** from Memphis seeks to enable the patient coordinators within each physician's office to provide patient monitoring and personalized care pathways in a simple patient app and web platform.

# + We proudly support Life Science Tennessee's 2020 LSTCON

To learn more about our products  
and our people visit:

[www.smith-nephew.com](http://www.smith-nephew.com)

**Smith+Nephew**



# THANK YOU TO OUR SPONSORS

**PRMA**  
RESEARCH • PROGRESS • HOPE



Biotechnology  
Innovation  
Organization

waller

Smith+Nephew



KraftCPAs  
PLLC



STAY CONNECTED

[www.lifesciencetn.org](http://www.lifesciencetn.org)

@LifeSciTN

LIFE SCIENCE  
TENNESSEE